But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against ...

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how ...

Sun Pharma considers expanding its US manufacturing footprint amid tariffs. Focus on UNLOXCYT launch and ILUMYA filing.

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on ...

Clawbacks for the 2024 hospital pharmaceutical budget came in marginally lower than 2023’s critical levels, remaining at an ...

Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...

The newly established division aims to produce 22mln units annually of cancer and immunosuppressive drugs that meet EU-GMP ...

Clever Culture is bringing automation to pharma microbiology, with its AI tech now used by global heavyweights such as ...

Mochida Pharmaceutical (TSE:4534) reported a net profit margin of 5.7%, up from 4.3% a year earlier, with earnings surging 36.5% over the past year. Despite this progress, shares currently trade at ¥3 ...

Sun Pharmas CEO discusses potential expansion of its US manufacturing amid tariff challenges, focusing on localised ...

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...